Ticker Details
Exelixis, Inc. Common Stock Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
IPO Date:	May 1, 2000
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$13.4B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.31 | 2.46%
Avg Daily Range (30 D):	$0.94 | 1.74%
Avg Daily Range (90 D):	$1.00 | 1.98%

Institutional Daily Volume
Avg Daily Volume:	2.07M
Avg Daily Volume (30 D):	1.78M
Avg Daily Volume (90 D):	1.92M

Trade Size
Avg Trade Size (Sh.):	150
Avg Trade Size (Sh.) (30 D):	61
Avg Trade Size (Sh.) (90 D):	57

Institutional Trades
Total Institutional Trades:	13,174
Avg Institutional Trade:	$3.23M
Avg Institutional Trade (30 D):	$8.85M
Avg Institutional Trade (90 D):	$7.52M
Avg Institutional Trade Volume:	.16M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$8.22M
Avg Closing Trade (30 D):	$33.32M
Avg Closing Trade (90 D):	$31.51M
Avg Closing Volume:	344.61K

News

Jul 29, 2026 @ 10:56 PM Kuehn Law Encourages Investors of EXELIXIS, Inc. t... Source: Kuehn Law, Pllc

Jun 10, 2026 @ 5:00 PM Metastatic Prostate Cancer Market Set for Robust G... Source: Delveinsight

May 15, 2026 @ 11:30 PM Prediction: This Stock Could Double By 2031 Source: Prosper Junior Bakiny

Apr 21, 2026 @ 5:42 PM Why Is Merck Stock Falling Tuesday? Source: Vandana Singh

Mar 18, 2026 @ 12:30 PM The Best Healthcare Stocks to Buy With $50 Right N... Source: Prosper Junior Bakiny

Financials
	TTM	Q2 2027	Q1 2027
Basic EPS		$.85	$.81
Diluted EPS		$.82	$.79
Revenue		$628.69M	$610.81M
Gross Profit		$608.03M	$590.86M
Net Income / Loss		$212.05M	$210.47M
Operating Income / Loss		$248.41M	$251.34M
Cost of Revenue		$20.66M	$19.95M
Net Cash Flow		$55.3M	$-256.34M
PE Ratio